![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Sumitomo, Protez Conclude Licensing Agreement for SMP-601
Sumitomo, Protez Conclude Licensing Agreement for SMP-601
May 23, 2005
Sumitomo Pharmaceuticals announced that it has signed a licensing agreement with Protez Pharmaceuticals for SMP-601, Sumitomo's proprietary antibiotic candidate. Founded in 2003 with the aid of BTG, Protez Pharmaceuticals is a U.S. venture company engaged in developing innovative antibiotics to combat drug-resistant and other difficult-to-treat infections.
()a href="http://www.japancorp.net/Article.Asp?Art_ID=10103" target="_blank">Japan Corporate News Network
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct